Cancer Genetics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares
November 02, 2020 16:00 ET
|
Cancer Genetics, Inc.
Rutherford, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics” or “the Company”), a leader in drug discovery and preclinical oncology and immuno-oncology...
Cancer Genetics, Inc. Increases Previously Announced Bought Deal to $3.0 Million
October 28, 2020 21:55 ET
|
Cancer Genetics, Inc.
Rutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in drug discovery and preclinical oncology and immuno-oncology services,...
Cancer Genetics, Inc. Announces $2.0 Million Bought Deal Offering
October 28, 2020 17:54 ET
|
Cancer Genetics, Inc.
Rutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in in drug discovery and preclinical oncology and immuno-oncology services,...
Cancer Genetics Announces Participation at the 22nd Annual Rodman & Renshaw Global Investment Conference
September 10, 2020 08:00 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
Cancer Genetics and StemoniX Announce Joint Proof-of-Concept Program
September 03, 2020 08:00 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., and MAPLE GROVE, MN, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, and...
Cancer Genetics and StemoniX Sign Definitive Agreement to Merge
August 24, 2020 08:00 ET
|
Cancer Genetics, Inc.
Combined Company Positioned to Offer Best-in-Class and Innovative Drug Discovery Solutions RUTHERFORD, NJ and MAPLE GROVE, MN, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the...
Cancer Genetics Reports Second Quarter 2020 Financial Results
August 14, 2020 07:30 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced...
Cancer Genetics Reports First Quarter 2020 Financial Results and Provides Strategic Business Updates
June 24, 2020 17:30 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., June 24, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today...
Cancer Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Strategic Business Updates
June 01, 2020 08:00 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., June 01, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced financial...
Cancer Genetics Issues Letter to Shareholders
February 20, 2020 09:00 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics” or the “Company”), a leader in drug discovery and preclinical oncology and immuno-oncology...